75A50126C00004↗

Name: 75A50126C00004: Late-Stage Development, Fda Marketing Authorization, Procurement, and Stockpile of Antibiotics for the Treatment of Drug-Resistant Secondary Bacterial Infections And/Or the Treatment or Pep of Infections Caused by Biothreat Pathogens.
Creator: SpendQuery
License: https://www.usa.gov/government-works

LATE-STAGE DEVELOPMENT, FDA MARKETING AUTHORIZATION, PROCUREMENT, AND STOCKPILE OF ANTIBIOTICS FOR THE TREATMENT OF DRUG-RESISTANT SECONDARY BACTERIAL INFECTIONS AND/OR THE TREATMENT OR PEP OF INFECTIONS CAUSED BY BIOTHREAT PATHOGENS.

Definitive Contract · Office of Assistant Secretary for Preparedness and Response · to Shionogi Inc (UEI V8H8DT6RCHW6) · data as of 2026-10-20

Obligated to date$156.10M2 actions

Current value$156.10Mwith options exercised

Potential value$481.68Mif every option is used

Period2026-04-06 → 2036-03-10current end date

What it is

Product or service: Health R&D Services; Health Care Services; Experimental Development (PSC AN13)
Industry: Research and Development in Biotechnology (Except Nanobiotechnology) (NAICS 541714)
Contracting office: Barda - Aspr / Daappo / Barda Dcma (75A501)
Competition: Full and open competition · 1 offer received
Pricing: Cost plus fixed fee
How it was bought: Standalone contract
Solicitation: 75A50125R00005
Where the work is: Morris, NJ · district NJ-11

Obligations by fiscal year

FY2026$156.10M

SpendQuery holds FY2023 on; earlier years are on USAspending.gov.

Subcontractors: where the money went next

No subawards reported for this award. Primes report subawards of $30,000 or more; many awards have none.

Every action

2 actions since 2026-04-06. Each is a modification or amendment with the money it added or took back.

Date	Modification	Kind	Amount	What the agency wrote
2026-08-21	P00001	Option exercised	$36.94M	LATE-STAGE DEVELOPMENT, FDA MARKETING AUTHORIZATION, PROCUREMENT, AND STOCKPILE OF ANTIBIOTICS FOR THE TREATMENT OF DRUG-RESISTANT SECONDARY BACTERIAL INFECTIONS AND/OR THE TREATMENT OR PEP OF INFECTIONS CAUSED BY BIOTHREAT PATHOGENS.
2026-04-06	0		$119.16M	LATE-STAGE DEVELOPMENT, FDA MARKETING AUTHORIZATION, PROCUREMENT, AND STOCKPILE OF ANTIBIOTICS FOR THE TREATMENT OF DRUG-RESISTANT SECONDARY BACTERIAL INFECTIONS AND/OR THE TREATMENT OR PEP OF INFECTIONS CAUSED BY BIOTHREAT PATHOGENS.

Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-10-20). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗

Putting the award page together from the records…